Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation.

This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Myeloid Leukemia Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Neoplasm, Residual Neoplasms Neoplasms by Histologic Type Neoplastic Processes Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

2 year–40 year

Sex eligibility

Female

Study type

Observational

Primary location

CHU lille

Lille, 59037, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient diagnosed with AML
At least one molecular marker identified at AML diagnosis
Patients who undergo ovarian tissue cryopreservation for fertility preservation in complete remission, before hematopoietic stem cell transplantation.

Exclusion criteria

Other diagnostic
No marker available at AML diagnosis
No bone marrow/ovarian fragment available at the time of complete remission

Treatment and study plan

Primary outcomes

Percentage of patients without detectable MRD in ovarian tissue

Time frame: Up to 6 months

Secondary outcomes

Percentage of patients with MRD detected in ovarian tissue and bone marrow.

Time frame: Up to 1 month

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Collaborators

Canceropôle Nord Ouest
Saint-Louis Hospital, Paris, France

Registry information

Official study title

Pilot Study to Assess Minimal Residual Disease on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

Acronym: FERTILAM

Important dates

Study start: 2021
Primary completion: 2022
Study completion: 2022
First posted: Dec 22, 2020
Registry last updated: Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed